Pharma Company And Drug Testing Industry Claim Trump’s Rescheduling Move Will ‘Increase Marijuana Abuse’
A pharmaceutical company and drug testing industry association have filed a federal court petition opposing the Trump administration's cannabis rescheduling initiative, arguing the policy change would increase marijuana abuse and cause health harms. The filing seeks to block rescheduling while ongoing litigation challenging the reform is pending.
Filed under Court Ruling in THC Minnesota's coverage of Minnesota's cannabis and hemp market.
Mentioned
Source Attribution
This summary was compiled from information published by Marijuana Moment. All facts and statements reflect the original source material. For complete details, refer to the original publication.
View Original Source →Related Updates
DEA Will Highlight Testimony On Marijuana’s Medical Benefits In Rescheduling Hearing, New Filing Shows
Anti-Marijuana Groups File Lawsuit To Block Trump Administration’s Hemp CBD And THC Medicare Coverage Plan
DEA highlights cannabis’s medical benefits & relative safety in rescheduling hearing (Newsletter: June 30, 2026)
Feds sued over Medicare cannabis product coverage (Newsletter: April 1, 2026)
AOC Slams Federal Drug Laws That Restrict Marijuana And Psychedelics Despite Their Medical Value
Judge Rejects Anti-Marijuana Groups’ Motion To Block CBD And THC Medicare Coverage Plan, Setting Hearing For 4/20
Stay current on Minnesota cannabis
Browse more court ruling updates, the full news feed, or the Minnesota cannabis timeline. Compare products across licensed dispensaries and read our consumer guides.